Category: Latest News
-
Lennar Stock Slides After Q4 Profit Miss Despite Stronger Sales
Shares of Lennar Corporation (NYSE:LEN) fell more than 2% in premarket trading after the U.S. homebuilder posted fourth-quarter earnings that came in below market expectations, overshadowing a revenue performance that exceeded forecasts in a difficult housing environment. For the quarter, Lennar reported adjusted earnings of $2.03 per share, missing the analyst consensus estimate of $2.21.…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, Markets Steady Ahead of Waller Speech; Lennar Disappoints, Micron in Focus
U.S. equity futures are trading cautiously as investors continue to digest recently released labor market data. Attention is turning to remarks from Federal Reserve Governor Christopher Waller, who is set to speak publicly for the first time since the central bank delivered an interest rate cut last week. In corporate news, shares of homebuilder Lennar…
-
Peugeot Family Renominates Robert Peugeot for Final Term on Stellantis Board
The Peugeot family has put forward Robert Peugeot for reappointment to the board of Stellantis (NYSE:STLA) for a final two-year term, the automotive group confirmed in a statement issued on Wednesday. Under the proposal, Robert Peugeot will take on the role of vice chairman at Stellantis. The family also reiterated its “long term commitment” to…
-
Transitioning the Cariboo Gold Project from developer to producer
In this episode of the Capital Compass we’re joined by one of the most recognized names in the mining industry — Sean Roosen — one of the original founders of Osisko Mining and the builder behind one of Canada’s most successful modern gold stories with Canadian Malartic. Sean is now leading Osisko Development (TSXV:ODV) (NYSE:ODV), which…
-
U.S. Stocks Close Mixed Following Another Choppy Session
Following the lackluster performance seen in the previous session, stocks continued to experience choppy trading on Tuesday. The major averages fluctuated over the course of the trading day before eventually closing on opposite sides of the unchanged line. While the tech-heavy Nasdaq rose 54.05 points or 0.2 percent to 23,111.46, the S&P 500 slipped 16.25…
-
Oil Drops Below $60 as Peace Hopes and Weak China Data Weigh on Prices
Oil prices slid beneath the $60-a-barrel mark on Tuesday, hitting their lowest levels since May, as optimism around potential Russia-Ukraine peace talks raised expectations that sanctions could eventually be relaxed. Brent crude futures were down $1.03, or about 1.7%, at $59.53 a barrel by 13:40 GMT. U.S. West Texas Intermediate crude also weakened, falling $1.06,…
-
Gold Holds Steady After Jobs Data, Trades Near All-Time Highs
Gold prices were little changed on Tuesday as investors absorbed a wave of U.S. economic releases, looking for signals on the future direction of Federal Reserve interest rate policy. At 09:05 ET (14:05 GMT), spot gold edged up 0.1% to $4,309.57 per ounce, while February gold futures also gained 0.1% to $4,340.50 an ounce. The…
-
Morgan Stanley Sees Compelling Value in Defense Stocks Ahead of 2026
Morgan Stanley believes U.S. defense equities present an attractive opportunity heading into 2026, arguing that current share prices do not adequately capture the outlook for continued expansion in U.S. defense spending, even amid ongoing political uncertainty. In a sector outlook, analyst Kristine Liwag said the bank views the group as undervalued, noting that it “provides…
-
Jumia Shares Jump as Craig-Hallum Starts Coverage With Bullish Outlook
Shares of Jumia Technologies AG (NYSE:JMIA) climbed 8.1% on Tuesday after Craig-Hallum analyst Ryan Sigdahl initiated coverage of the African e-commerce group with a Buy rating and a price target of $18 per share. In his initiation note, Sigdahl pointed to Jumia’s “decade-plus long growth runway” within Africa’s still underpenetrated e-commerce market, arguing that the…
-
Royalty Pharma Shares Edge Higher on Acquisition of Oncology Drug Royalties
Shares of Royalty Pharma plc (NASDAQ:RPRX) gained 2.4% in pre-market trading on Tuesday after the company said it had secured royalty interests linked to two emerging cancer treatments. The firm is acquiring an existing low single-digit royalty on Nuvalent’s oncology drugs neladalkib and zidesamtinib in a transaction valued at up to $315 million. Both therapies…